Orexo AB Competitors
| ORXOF Stock | USD 2.29 -0.94 -29.10% |
Orexo AB and Poolbeg Pharma Correlation Summary
Good diversification
The correlation between ORXOF and POLBF is -0.03, which Macroaxis classifies as Good diversification for the selected horizon. The overlap area represents the portion of risk that may be diversified away when both instruments are held together and nothing else in the portfolio changes.
Investors who believe in mean reversion view Orexo AB's price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
Orexo AB Competition Correlation Matrix
Correlation analysis between Orexo AB and its competitors provides context for understanding whether diversification is real or only superficial inside the same peer group. The business currently sits in the Healthcare sector and the Drug Manufacturers—Specialty & Generic industry. In practical terms, lower correlation may offer better diversification while higher correlation may leave the portfolio more exposed to one shared driver.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Strong stock returns do not always mean Orexo AB OTC Stock is outperforming its peers on a fundamental level. A thorough review of Orexo AB's risk-adjusted indicators provides a clearer picture of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SHIEF | 2.16 | 0.89 | 0.00 | 0.95 | 0.00 | 7.14 | 57.62 | |||
| PFGTF | 7.45 | 3.09 | 0.00 | 0.68 | 0.00 | 0.00 | 165.49 | |||
| GGBXF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| GRUSF | 5.00 | 0.36 | 0.08 | -1.44 | 5.22 | 8.70 | 48.44 | |||
| BIOYF | 1.78 | 0.35 | 0.13 | -1.08 | 2.45 | 4.81 | 24.59 | |||
| LOVFF | 1.57 | 0.03 | 0.05 | -0.40 | 1.86 | 3.85 | 13.41 | |||
| IMPZY | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TOKIF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| JUSHF | 5.30 | -0.28 | 0.00 | 2.97 | 0.00 | 12.73 | 59.12 | |||
| POLBF | 1.80 | 0.91 | 0.00 | -6.01 | 0.00 | 0.00 | 55.53 |
Orexo AB Competitive Analysis
Sizing up Orexo AB against Shield Therapeutics, Pacific Edge, and Green Growth reveals meaningful differences in scale and efficiency. At a 58.7 M valuation, Orexo AB brings in 565.0 M on the top line. With a -65.35% return on equity and -28.45% net margin, Orexo AB faces a more difficult earnings environment than some peers. Orexo AB pulls in 565.0 M in revenue while Shield Therapeutics reports 1.5 M. On the bottom line, Orexo AB retains -28.45% while Pacific Edge manages -129.70%. On pure scale, Orexo AB is the larger business with market caps of 58.7 M versus 41,222.| Better Than Average | Worse Than Peers | View Performance Chart |
Orexo AB Competition Peer Performance Charts
How to Analyze Orexo AB Against Peers
Orexo AB's peer analysis compares Orexo AB with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Orexo AB trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Orexo AB leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Competitor benchmarking for Orexo AB often reveals which operating metrics are genuinely differentiated and which appear similar across the peer group. The competition page for Orexo AB helps identify potential substitutes and alternatives from both a business and positioning perspective. Income sustainability for Orexo AB looks different when placed in context against peer group payout and retention trends. Competition analysis can clarify whether Orexo AB is priced richly or cheaply relative to similar exposures. For peer comparison, Orexo AB has a market cap of 58.7 M, P/E of 58.66, profit margin of -28.45%.
This section for Orexo AB is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules.